Castle Biosciences to Present at the 22nd Annual Needham Virtual Healthcare Conference

Rhea-AI Summary

Castle Biosciences, Inc. (Nasdaq: CSTL) has announced that CEO Derek Maetzold and CFO Frank Stokes will present a company overview at the 22nd Annual Needham Virtual Healthcare Conference on April 19, 2023, at 4:30 p.m. Eastern time.

The presentation will be accessible through a live audio webcast on Castle Biosciences' website, with a replay available post-event.

Castle Biosciences is focused on innovative diagnostic tests that guide patient care, primarily in skin and mental health conditions. Its portfolio includes tests for skin cancers and Barrett’s esophagus, with ongoing research for new diagnostics in high-need areas like psoriasis and atopic dermatitis.

FRIENDSWOOD, Texas--(BUSINESS WIRE)-- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that Derek Maetzold, president and chief executive officer, and Frank Stokes, chief financial officer, are scheduled to present a company overview at the 22nd Annual Needham Virtual Healthcare Conference on Wednesday, April 19, 2023, at 4:30 p.m. Eastern time.

A live audio webcast of the Company’s presentation will be available by visiting Castle Biosciences’ website at https://ir.castlebiosciences.com/events-presentations/default.aspx. A replay of the webcast will be available following the conclusion of the live broadcast.

About Castle Biosciences

Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.

Castle’s current portfolio consists of tests for skin cancers, uveal melanoma, Barrett’s esophagus and mental health conditions. Additionally, the Company has active research and development programs for tests in other diseases with high clinical need, including its test in development to predict systemic therapy response in patients with moderate-to-severe psoriasis, atopic dermatitis and related conditions. To learn more, please visit www.CastleBiosciences.com and connect with us on LinkedIn, Facebook, Twitter and Instagram.

DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, MyPath Melanoma, DiffDx-Melanoma, DecisionDx-UM, DecisionDx-PRAME, DecisionDx-UMSeq, TissueCypher and IDgenetix are trademarks of Castle Biosciences, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230412005085/en/

Investor Contact:

Camilla Zuckero

czuckero@castlebiosciences.com

Media Contact:

Allison Marshall

amarshall@castlebiosciences.com

Source: Castle Biosciences, Inc.

FAQ

What is the date and time of Castle Biosciences' presentation at the Needham Virtual Healthcare Conference?

Castle Biosciences will present on April 19, 2023, at 4:30 p.m. Eastern time.

Where can I watch the Castle Biosciences presentation?

The presentation can be viewed live on Castle Biosciences' website.

What is Castle Biosciences' focus in the healthcare sector?

Castle Biosciences focuses on developing innovative diagnostic tests that guide patient care.

Which conditions does Castle Biosciences currently test for?

Castle Biosciences tests for skin cancers, uveal melanoma, Barrett’s esophagus, and mental health conditions.

Is Castle Biosciences working on new diagnostic tests?

Yes, Castle Biosciences has active R&D programs for tests in diseases with high clinical need, including psoriasis.